Connect Biopharma Holdings Limited
CNTB
$2.12
-$0.08-3.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -99.10% | -99.75% | -96.99% | -91.85% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.10% | -99.75% | -96.99% | -91.85% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -99.10% | -99.75% | -96.99% | -91.85% | -- |
| SG&A Expenses | 10.94% | 16.70% | 16.44% | 13.45% | 14.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.72% | 28.38% | 0.22% | -15.49% | -32.16% |
| Operating Income | -266.62% | -201.65% | -89.86% | -39.86% | 72.21% |
| Income Before Tax | -279.81% | -258.86% | -118.82% | -76.17% | 69.41% |
| Income Tax Expenses | -22.67% | -11.66% | 90.34% | 134.48% | 109.32% |
| Earnings from Continuing Operations | -275.46% | -255.00% | -118.64% | -76.44% | 69.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -275.46% | -255.00% | -118.64% | -76.44% | 69.03% |
| EBIT | -266.62% | -201.65% | -89.86% | -39.86% | 72.21% |
| EBITDA | -276.73% | -208.57% | -92.12% | -40.68% | 72.95% |
| EPS Basic | -271.44% | -252.26% | -117.09% | -75.38% | 69.21% |
| Normalized Basic EPS | -363.51% | -349.57% | -153.42% | -77.81% | 75.35% |
| EPS Diluted | -271.44% | -252.26% | -116.14% | -74.02% | 69.32% |
| Normalized Diluted EPS | -358.48% | -344.09% | -151.46% | -76.71% | 75.08% |
| Average Basic Shares Outstanding | 1.23% | 0.81% | 0.57% | 0.43% | 0.35% |
| Average Diluted Shares Outstanding | 0.99% | 0.57% | 0.33% | 0.20% | 0.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |